
usd aug pm et
summari global develop market anim vaccin medicin diagnost livestock
produc veterinarian
price-to-earnings oper ep
risk assess reflect compani strong
posit global anim heath market
possess attract product divers geograph
reach risk rate also reflect strong growth
potenti see global pet ownership rate middl
class expand less develop market also less
expos research develop patent
reimburs risk face tradit human
pharmaceut firm posit factor
somewhat mitig potenti new restrict
antibiot food-produc anim consum
trend away tradit meat product
nov ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug stock trade
sale grew yoy follow growth
full-year growth led
companion anim sale revenu
yoy help
acquisit abaxi juli
maker diagnost instrument veterinari
care companion also see strong organ
growth driven view healthi consum
spend translat greater pet
ownership companion growth
off-set drop livestock revenu
think intern companion
revenu remain excel growth
opportun pet ownership rate rise
median incom view think
foreign market expand middl class
china brazil drive long-term
demand growth companion anim health
livestock saw sale drop yoy
recov swine diseas
outbreak china subsid
invest heavili new product
capabl indic capital-expenditure grow
year end june think
invest yield strong margin
expans opportun
think durabl leadership posit
anim health product see
share near full valu current forward
price-to-earnings multipl roughli higher histor
averag expect companion anim
segment lead futur growth think
global pet ownership trend favor
end-custom pet owner especi
like accept price increas rather
withhold medic benefit belov
pet give segment strong price power
also expect oper margin improv
driven lead scale larg
invest capital-expenditure risk
view includ demand weak beef
pork product due shift consum tast
diseas outbreak livestock herd greater
regulatori scrutini antibiot livestock
declin pet ownership rate driven
target price ep
estim -- histor forward price-to-earnings
averag due strong global trend pet
ownership relat product expect
recent intern expans
companion anim segment fuel
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview zoeti among top global competitor discoveri develop
manufactur market anim health medicin vaccin focu livestock
companion anim compani market divers rang product livestock speci cattl
beef dairi swine poultri sheep fish companion anim speci dog cat
hors chief product categori anti-infect vaccin parasiticid medic feed addit
pharmaceut product also offer diagnost devic anim health product
compani directli market product countri product sold anoth nation
non-direct channel sale account total emerg
market brazil china mexico account brazil largest intern market
sale account total
livestock farm anim product mainli cattl swine account total sale
compris item cattl swine poultri fish sheep select livestock product includ
ceftiofur draxxin antibiot cattl swine sheep bovishield improvac respisur rispov
vaccin cattl swine cydectin dectomax parasiticid cattl sheep
long-term macro driver livestock product includ growth global popul rise standard
live rise demand improv nutrit particularli anim protein
product companion pet primarili dog cat repres sale princip brand
includ clavamox covinia terramycin anti-infect vanguard vaccin revolution/stronghold
parasiticid growth busi driven econom develop relat increas
treatment companion anim advanc anim health medicin vaccin
beyond livestock companion anim product oper gener rema revenu
total busi like contract manufactur
corpor strategi compani may pursu acquisit technolog licens arrang
strateg allianc divestitur busi part overal strategi drive growth
leverag road global footprint zoeti strive provid custom innov product
servic also place great emphasi spawn extens diversifi product
portfolio line latter strategi compani pursu develop new vaccin
emerg infecti diseas anim spent million revenu
million revenu
juli complet acquisit abaxi inc california corpor focus
develop manufactur market diagnost instrument veterinari point-of-car servic
acquir outstand common share abaxi per share cash result
abaxi becom wholly-own subsidiari acquisit enhanc presenc grow
market veterinari diagnost acquisit date fair valu consider transfer
approxim billion paid primarili new debt billion well cash hand
competit landscap prior zoeti apart larg pharmaceut firm
compani still primarili compet anim health divis within larg pharmaceut firm
competitor includ merck anim health divis merial anim health divis sanofi
elanco former subsidiari public bayer anim health novarti anim health
estim largest player anim health market term revenu follow
financi trend sale risen billion billion repres
three-year compound annual growth rate adjust pre-tax incom per share risen
repres three-year compound-annual-growth-rate improv profit margin
primari driver growth earn per share outpac sale growth leverag
level modest view adjust oper earn cover interest expens
execut vice-president chief
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc februari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook sub-industri
next year neutral expect
modest revenu growth
driven slowdown novel drug approv
activ potenti new price regul
neg partial off-set
upcom favor period patent
expir also
expect gener maker continu struggl
grow earn lower cost foreign
competit continu prosper
banner year new brand
drug fda see slowdown
total novel drug approv
fda signific
surg versu combin approv
growth sub-industri
versu averag
new drug launch appear slow
howev fda approv
novel drug year june
period also observ
yoy declin spend
pharmaceut think
portend effort maintain margin sluggish
revenu growth year ahead
pharmaceut also face increas
risk potenti new drug price regul
juli presid indic
administr work new rule set
govern drug price use intern
index accord wall street journal
studi govern health system develop
countri like england norway canada often
pay less major brand
 center medicar medicaid
servic think intern
index rule would like drive higher price
foreign market lower one
would like still neg
overal impact sub-industri revenu
administr effort date lower drug
price regul
success intern index
signific risk weigh outlook
balanc neg factor face
brand drug maker expect
upcom favor period patent
expir typic biggest
revenu headwind base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
posit brand drug sale
beyond brand firm make lion
share sub-industri market cap outlook
gener maker neg previous
anda would declin sever deflat
drove competitor industri
seem play
six-month move averag anda june
recent peak
longer think fewer competitor
enough stabil gener industri
howev india-bas gener maker
like take market share develop nation
firm due lower product cost --
india-bas produc oper
estim averag gross margin
versu top western
drop broader composit
year-to-d juli
pharmaceut
gain
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
rais target price above-p
forward ep estim above-p growth ep
vs ahead estim rais ep estim
ep estim sale rose
believ gain market share strong demand new parasiticid
vaccin dermatolog product sale rose companion
anim product sale livestock product sale sale
rose companion anim product livestock modest
soft sale cattl product partial off-set strong sale poultri swine
product complet acquisit abaxi develop veterinari
diagnost instrument juli see veterinari diagnost one
fastest grow area anim health industri /jeffrey loo cfa
et cfra keep hold opinion share zoeti inc
agre acquir abaxi abax nr share cash
total abax lead provid veterinari diagnost
forecast fy sale oper margin
consensu ep although view veterinari diagnost fast
grow segment within anim health forecast compound annual
sale growth next three year believ
pay sizeabl premium fy ep particularli sinc abax
oper margin well oper margin
expect deal subject approv close
year-end expect materi impact result
see deal accret earn believ larger global
presenc benefit abax oper deriv sale
analyst research note compani news
et cfra keep hold opinion share zoeti inc
lift target ep estim
histor forward price-to-earnings averag due rapid growth pet-rel sale
rais ep estim
ep vs beat consensu sale rose yoy
led companion anim total sale grew yoy aid
abaxi acquisit juli livestock sale continu
declin howev sale drop yoy drop yoy
cattl swine product poultri fish saw sale rise strong demand
though reflect long-term trend toward healthier eat view
adjust pre-tax incom per share grew yoy slightli slower
revenu jump sg restructur expens compress margin yoy
expect margin improv cost synergi abaxi
realiz see alreadi reflect valuat think
near fair valu /colin scarola
pm et cfra keep hold opinion share zoeti inc
lift target price ep estim --
histor forward price-to-earnings averag due rapid growth pet-rel sale
ep vs beat consensu maintain
ep estim revenu rose yoy led growth companion
anim sale aid acquisit abaxi juli
livestock sale fell yoy howev driven weaker demand
 particularli cattl swine product convers chicken
fish sale increas think reflect trend toward healthier eat
despit revenu growth adjust pre-tax incom fell yoy oper
expens continu grow faster sale expect margin improv later
howev integr abaxi strong market
posit long-term growth outlook view especi companion
think alreadi fulli reflect premium valuat /colin
et cfra keep hold opinion share zoeti inc
lift target ep estim -- line
histor forward price-to-earnings averag ep vs beat
consensu rais ep estim keep
sale rose yoy led growth companion anim
sale aid acquisit abaxi juli maker
veterinari diagnost livestock sale fell yoy howev driven
softer demand cattl custom despit materi revenu growth
quarter estim adjust pre-tax incom per share fell yoy oper
expens grew materi faster sale pre-tax margin declin
six percentag point expect margin improv compani
progress abaxi integr strong market
posit long-term growth outlook view especi companion
premium valuat peer keep us neutral share /colin
keep target ep estim
long-term averag forward price-to-earnings expect recent acquisit
expans companion anim segment fuel above-averag growth
ep vs ahead consensu maintain ep
estim lower start sale rose
yoy led robust growth companion segment total revenue
grew sale yoy aid acquisit
ca-bas abaxi juli well robust growth intern companion
sale believ intern companion sale remain excel growth
opportun companion lead growth livestock
segment tot revenue livestock sale growth deceler yoy
high single-digit weaker cattl demand like
market posit growth outlook high valuat keep us neutral
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
